Drug intelligence / Profile preview

cs060304

Development stage: Phase 1
Lead developer: Cascade Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

CS060304 is a novel thyroid hormone receptor beta (THR-β) agonist with highly specific enrichment in liver tissue. It's being developed for metabolic conditions including hypercholesterolemia and nonalcoholic steatohepatitis (NASH). Preclinical data shows promising results in improving NAS scores and fibrosis in NASH mouse models, with characteristics of low effective dosage, significant efficacy, and good tolerability. The drug target is the same as MGL-3196 (Resmetirom), but CS060304 reportedly demonstrates significantly positive preclinical data compared to Resmetirom.

Targets

THRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on cs060304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cs060304.

Explore the full profile